---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-084861"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-07-20T11:13:05+00:00"
generated_at: "2026-07-20T11:15:21.948387+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Armata Pharmaceuticals Reports Progress on AP-SA02 Phase 3 Study and Promotes David House to CFO

## Summary
- Submitted complete Phase 3 superiority protocol to FDA for AP-SA02, addressing all End-of-Phase 2 meeting comments.
- Completed four engineering runs of AP-SA02 at cGMP facility; clinical trial material production is next step.
- Received $2.5 million continuation award from DoD, bringing total funding to $28.7 million for Phase 3 readiness.
- Promoted David House to Chief Financial Officer; he previously served as SVP, Finance since August 2024.
- Phase 3 superiority study remains on track to initiate in the second half of 2026.

## SEC filing metadata
- accession: 0001104659-26-084861
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-07-20T11:13:05+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926084861/0001104659-26-084861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926084861/tm2620782d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-084861
- JSON: https://secwatch.observer/filing/0001104659-26-084861.json
- Plain text: https://secwatch.observer/filing/0001104659-26-084861.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.